Clinical Trial Update: Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating subcutaneous immunotherapy with gpASIT+ for grass pollen-induced allergic rhinoconjunctivitis shows ongoing efficacy and safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis
• Hay Fever

Drugs mentioned

• gpASIT+™ (gpASIT+™)

Snippet

Sponsor: ASIT Biotech S.A. | Conditions: Hay Fever | Phase 3 | Status: UNKNOWN